Quantification of HER 2 by Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded ( FFPE ) Breast Cancer Tissues *

The ability to accurately quantify proteins in formalin-fixed paraffin-embedded tissues using targeted mass spectrometry opens exciting perspectives for biomarker discovery. We have developed and evaluated a selected reaction monitoring assay for the human receptor tyrosine-protein kinase erbB-2 (HER2) in formalin-fixed paraffin-embedded breast tumors. Peptide candidates were identified using an untargeted mass spectrometry approach in relevant cell lines. A multiplexed assay was developed for the six best candidate peptides and evaluated for linearity, precision and lower limit of quantification. Results showed a linear response over a calibration range of 0.012 to 100 fmol on column (R: 0.99–1.00).The lower limit of quantification was 0.155 fmol on column for all peptides evaluated. The six HER2 peptides were quantified by selected reaction monitoring in a cohort of 40 archival formalin-fixed paraffin-embedded tumor tissues from women with invasive breast carcinomas, which showed different levels of HER2 gene amplification as assessed by standard methods used in clinical pathology. The amounts of the six HER2 peptides were highly and significantly correlated with each other, indicating that peptide levels can be used as surrogates of protein amounts in formalin-fixed paraffin-embedded tissues. After normalization for sample size, selected reaction monitoring peptide measurements were able to correctly predict 90% of cases based on HER2 amplification as defined by the American Society of Clinical Oncology and College of American Pathologists. In conclusion, the developed assay showed good analytical performance and a high agreement with immunohistochemistry and fluorescence in situ hybridization data. This study demonstrated that selected reaction monitoring allows to accurately quantify protein expression in formalin-fixed paraffin-embedded tissues and represents therefore a powerful approach for biomarker discovery studies. The untargeted mass spectrometry data is available via ProteomeXchange whereas the quantification data by selected reaction monitoring is available on the Panorama Public website. Molecular & Cellular Proteomics 14: 10.1074/mcp.O115.049049, 2786– 2799, 2015.

[1]  E. Diamandis,et al.  Toward an integrated pipeline for protein biomarker development. , 2015, Biochimica et biophysica acta.

[2]  Marta Cuadros,et al.  Systematic Review of HER2 Breast Cancer Testing , 2009, Applied immunohistochemistry & molecular morphology : AIMM.

[3]  Susan E. Abbatiello,et al.  Targeted Peptide Measurements in Biology and Medicine: Best Practices for Mass Spectrometry-based Assay Development Using a Fit-for-Purpose Approach* , 2014, Molecular & Cellular Proteomics.

[4]  Ruedi Aebersold,et al.  Options and considerations when selecting a quantitative proteomics strategy , 2010, Nature Biotechnology.

[5]  M. Moran,et al.  Selected Reaction Monitoring (SRM) Analysis of Epidermal Growth Factor Receptor (EGFR) in Formalin Fixed Tumor Tissue , 2012, Clinical Proteomics.

[6]  Christoph H Borchers,et al.  Multiple Reaction Monitoring-based, Multiplexed, Absolute Quantitation of 45 Proteins in Human Plasma* , 2009, Molecular & Cellular Proteomics.

[7]  Alexander Scherl,et al.  Applications of mass spectrometry for quantitative protein analysis in formalin-fixed paraffin-embedded tissues , 2014, Proteomics.

[8]  Andrew R. Jones,et al.  ProteomeXchange provides globally co-ordinated proteomics data submission and dissemination , 2014, Nature Biotechnology.

[9]  J. Ross,et al.  The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. , 2009, The oncologist.

[10]  P. Selby,et al.  Impact of pre‐analytical factors on the proteomic analysis of formalin‐fixed paraffin‐embedded tissue , 2013, Proteomics. Clinical applications.

[11]  Ruedi Aebersold,et al.  Mass spectrometry-based proteomic quest for diabetes biomarkers. , 2015, Biochimica et biophysica acta.

[12]  Jorge S Reis-Filho,et al.  Triple-negative breast cancer. , 2010, The New England journal of medicine.

[13]  B. Ljung,et al.  Breast cancer version 3.2014. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[14]  K. Elenitoba-Johnson,et al.  Identification of proteins from formalin-fixed paraffin-embedded cells by LC-MS/MS , 2005, Laboratory Investigation.

[15]  A. Tanca,et al.  Setting proteins free: Progresses and achievements in proteomics of formalin‐fixed, paraffin‐embedded tissues , 2012, Proteomics. Clinical applications.

[16]  S. Hewitt,et al.  Application of selected reaction monitoring for multiplex quantification of clinically validated biomarkers in formalin-fixed, paraffin-embedded tumor tissue. , 2013, The Journal of molecular diagnostics : JMD.

[17]  Brendan MacLean,et al.  Bioinformatics Applications Note Gene Expression Skyline: an Open Source Document Editor for Creating and Analyzing Targeted Proteomics Experiments , 2022 .

[18]  B. Domon,et al.  Selected reaction monitoring applied to proteomics. , 2011, Journal of mass spectrometry : JMS.

[19]  Kay Dickersin,et al.  Shaping the future of biomarker research in breast cancer to ensure clinical relevance , 2007, Nature Reviews Cancer.

[20]  P. Chu,et al.  Keratin expression in human tissues and neoplasms , 2002, Histopathology.

[21]  D. Hicks,et al.  HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. , 2008, American journal of clinical pathology.

[22]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[23]  C. Borchers,et al.  Improving the biomarker pipeline. , 2010, Clinical chemistry.

[24]  E. Espinosa,et al.  Protein phosphorylation analysis in archival clinical cancer samples by shotgun and targeted proteomics approaches. , 2011, Molecular bioSystems.

[25]  P. Roller,et al.  Formaldehyde fixation. , 1985, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[26]  S. Carr,et al.  Protein quantitation through targeted mass spectrometry: the way out of biomarker purgatory? , 2008, Clinical chemistry.

[27]  T. O'Leary,et al.  Toward improving the proteomic analysis of formalin-fixed, paraffin-embedded tissue , 2013, Expert review of proteomics.

[28]  A. Hoofnagle,et al.  Measurement of thyroglobulin by liquid chromatography-tandem mass spectrometry in serum and plasma in the presence of antithyroglobulin autoantibodies. , 2013, Clinical chemistry.

[29]  M. Hung,et al.  The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines , 2010, Breast cancer : basic and clinical research.

[30]  A. Lucacchini,et al.  Proteomic studies of formalin-fixed paraffin-embedded tissues , 2013, Expert review of proteomics.

[31]  S. Baker Improving the biomarker pipeline to develop and evaluate cancer screening tests. , 2009, Journal of the National Cancer Institute.

[32]  A. Tanca,et al.  Comparability of differential proteomics data generated from paired archival fresh-frozen and formalin-fixed samples by GeLC-MS/MS and spectral counting. , 2012, Journal of proteomics.

[33]  Kendall W. Cradic,et al.  Quantification of serum 1-84 parathyroid hormone in patients with hyperparathyroidism by immunocapture in situ digestion liquid chromatography-tandem mass spectrometry. , 2010, Clinical chemistry.

[34]  R. Aebersold,et al.  Selected reaction monitoring for quantitative proteomics: a tutorial , 2008, Molecular systems biology.

[35]  Daniel C. Liebler,et al.  Equivalence of Protein Inventories Obtained from Formalin-fixed Paraffin-embedded and Frozen Tissue in Multidimensional Liquid Chromatography-Tandem Mass Spectrometry Shotgun Proteomic Analysis* , 2009, Molecular & Cellular Proteomics.

[36]  Markus Müller,et al.  EasyProt--an easy-to-use graphical platform for proteomics data analysis. , 2013, Journal of proteomics.

[37]  T. Veenstra,et al.  Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue , 2014, PloS one.

[38]  Brendan MacLean,et al.  Panorama: A Targeted Proteomics Knowledge Base , 2014, Journal of proteome research.

[39]  Peter Hoffmann,et al.  Proteomic developments in the analysis of formalin-fixed tissue. , 2015, Biochimica et biophysica acta.

[40]  A. Agresti An introduction to categorical data analysis , 1997 .

[41]  D. DeVoe,et al.  Proteome Analysis of Microdissected Formalin-fixed and Paraffin-embedded Tissue Specimens , 2007, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[42]  Kurt Zatloukal,et al.  Variability of protein and phosphoprotein levels in clinical tissue specimens during the preanalytical phase. , 2012, Journal of proteome research.

[43]  Michael Pawlak,et al.  Multiple Protein Analysis of Formalin-fixed and Paraffin-embedded Tissue Samples with Reverse phase Protein Arrays , 2013, Molecular & Cellular Proteomics.